GiveBetter x USA

1Day Sooner

Clinical-trial reform, participant support and medical evidence

Research time: ~19 min on GPT-6.1 Sol
  • Research — reviewed programs, finances and impact evidence.
  • Source audit — checked claims, assumptions and calculations.
  • Modeling — estimated costs, QALYs and uncertainty.

Updated: 2026-09-30

Donate

Summary

What do they do? 1Day Sooner combines clinical-trial policy, participant representation and support for infectious-disease research. Its U.S. work develops FDA evidence and trial-policy proposals; its international work includes challenge models and vaccine access. Donations support its policy researchers, participant-representation work and clinical-data projects.

Why we’re interested in this organization:

  • CPO study collaborations, a participant council and clinical-data infrastructure give the organization concrete operations beyond general advocacy.

  • Original 2022–2024 returns and current cumulative-funding disclosures make spending and entity distinctions inspectable.

  • Better clinical evidence could affect many development programs, and participant representation addresses a neglected incentive problem.

Our main reservations:

  • The health-and-income estimate depends on hypothetical causal scale and incidence; no study identifies the combined organization-specific return.

  • International beneficiaries, clinical risks and shared work with other advocates sharply limit simple attribution.

  • Recent large gifts and an affiliate grant-label mismatch leave current charity funding room unverified.

What do you get for your dollar? $895K per DALY in USA. DALY is our one-year comparison unit. QALY-based health gains and income-welfare equivalents retain their original assumptions; they are not measured clinical DALYs. Annual-cost health-and-income welfare comparison; causal effects are judgment-based scenarios, not measured donation returns.

Policy work and data reuse could reduce the resources needed for reliable trials, including failed products, alongside earlier useful treatment. The affected trials and savings are hypotheses, not measured program returns.

1. What do they do?

1Day Sooner works on the people and institutions that produce medical evidence. Its Cooperative Participant Organization (CPO) places staff scientists alongside study teams to support recruitment, representation and communications. The CPO FAQ clarifies that these are collaborations, that 1Day does not conduct day-to-day trial research, and that most CPO work relies on grants with collaborators; philanthropy may subsidize some services. A donor therefore supports complementary study capacity rather than directly buying a vaccine trial.

Its U.S. clinical-trial policy agenda includes FDA data transparency, wider use of real-world evidence, participant compensation and IRB transparency. Policy proposals, convening and agency submissions are outputs, not enacted reforms or patient benefits. The ten-year aspiration to produce far more evidence at much lower cost is a stretch goal, not the expected result of a marginal donation.

Other work is international. Challenge-model development concerns hepatitis C, Australian strep A studies and TB research in Malawi. Vaccine-policy research includes African malaria-vaccine rollout. These may have considerable global value, but people vaccinated abroad are not U.S. beneficiaries. We quantify only a hypothetical clinical-policy pathway and leave other benefits unpriced rather than assigning them invented health outcomes.

2. Monitoring and information sharing

The strongest observable evidence concerns operations. The Participant Council has 15 members from eight countries, including four U.S. members; it meets three to four times annually and compensates attendance. Its work on representation, ethics and fair compensation is a real participant-governance output. Council composition is not an estimate of the organization's U.S. spending or patient share. For CPO, useful monitoring would count funded collaborations, eligible volunteers enrolled and retained, recruitment time compared with similar studies, and whether participant recommendations change protocols.

CTD Commons aims to acquire and share regulatory dossiers from failed biotechnology companies, combining legal acquisition with data engineering. The January 2026 launch identifies both 1Day and Renaissance Philanthropy as backers. Dossiers acquired, properly redacted and reused would be stronger metrics than launch announcements. We found no public causal estimate of development time saved or additional effective treatments from its archive.

Independent evidence helps distinguish proposed from active research. Oxford's July 2026 HIT update describes first-stage recruitment of people already infected with hepatitis C to donate blood for inoculum development. It does not demonstrate a successful vaccine or completed infection of healthy volunteers. 1Day's older Hep C page still anticipates recruitment in 2024, so that forecast cannot verify today's milestone. The linked ISRCTN record redirected to a holding page during review.

The FDA's September 15, 2026 Expedited IND pilot accepts applications until October 30 and tests whether rolling pre-IND preparation makes early trials more predictable. It is a relevant policy development, but no completed pilot evaluation yet establishes acceleration through later trials, approval and treatment use. A review should follow those stages and adverse outcomes, not award QALYs at the announcement.

3. Qualitative assessment

The case is institutional leverage with substantial causal uncertainty. A good research model or reusable archive can benefit several projects, and timely removal of avoidable trial friction can matter. Earlier evidence can also correctly stop an ineffective candidate, which is valuable without producing the model's earlier-treatment benefit. Reliable evidence and patient access matter more than the number of trials started.

Participant advocacy is a distinctive strength: study sponsors do not necessarily internalize volunteer welfare or the value of transparent results. The informed-consent guide discusses quarantine, withdrawal and uncertain long-term effects. An affiliated systematic review covered 15,046 challenged participants in 308 studies, found 24 reported serious adverse events and no reported deaths or permanent damage, but emphasized incomplete reporting. These historical observations are neither zero-risk evidence nor a safety forecast for a novel pathogen. The authors disclose 1Day affiliations; this is useful research, not an independent assessment of the charity.

Risks include participant morbidity and inconvenience, rare or unrecognized long-term harms, exclusion of less healthy people, and premature conclusions from surrogate endpoints or nonrepresentative samples. Compensation may improve access and fairness while requiring careful consent and risk review. Regulatory reform can save time, but weakening valid safeguards or encouraging use of ineffective products could produce negative health value. Ethical representation and scientific validity therefore belong in monitoring alongside speed.

Attribution is shared. The briefs page identifies policy papers prepared for an IFP–Renaissance project, and the symposium includes multiple organizations. FDA, investigators, other advocates and existing funders can advance the same work. We would not sum IFP and 1Day health estimates for the same reform without allocating their joint contribution. This beta review supports continued investigation of a speculative opportunity; it is not a demonstrated cost-effective U.S. health intervention.

4. What do you get for your dollar?

Our central health-and-income estimate is $900K per DALY, using one modeled equivalent year. The previous health-only review was $6.4M; the original alpha comparison was $320K. These are different model versions, not measurements showing that impact changed by those ratios. Income-equivalent years are wellbeing comparisons, not observed QALYs or DALYs.

Correcting the cost boundary. We charge the latest inspected annual charity expense, $2,424,138, once. The previous review also multiplied the denominator by an arbitrary new-donation additionality factor based partly on grant receipts. That mixes annual-work cost-effectiveness with a marginal-gift model. We remove that factor from the annual-cost central case; implementation probabilities and the organization's contribution still apply. Receiving a grant does not prove the year's work has low value. The old funding haircut remains a sensitivity, and current room for more funding still needs a costed work package. This is not a promise that any gift size scales linearly.

Income pathway: cheaper reliable medical evidence. 1Day Sooner's trial-abundance program explicitly aims to reduce evidence-generation costs and make better use of existing data. Efficient trials can save resources even when a product fails. We therefore do not multiply this income channel by the 7.9% drug-approval probability or the separate clinical-usefulness factor used for patient health.

The central hypothesis is 20 affected trial-equivalents at $20.0M each, with 10% avoidable resource cost: $40.0M gross savings, less $2.0M of extra implementation, regulator, dossier, challenge-agent and participant-resource costs. HHS's historical operational model demonstrates the order of magnitude of possible trial-operation savings, not this organization's achieved saving. Twenty affected trials and a 10% saving are judgments; they are not the entire trial industry and do not imply that every trial is changed by 1Day Sooner. Before/after trial-cost and dossier-reuse data would replace these assumptions.

Of the $38.0M conditional net resource saving, we assign half to U.S. incidence and half of that to independent net disposable-income benefit: $9.5M. The second adjustment excludes reinvestment already represented by health, offsetting labor/provider losses and savings not reaching household consumption. Spread over 10,000 owners or payers with $100,000 income, that is a one-year $950 gain. This relatively affluent baseline avoids valuing pharmaceutical profits as if received by poor households. The 25% useful-reform probability and 15% organizational contribution apply once, giving a 3.75% causal share; realization is three years away, discounted at 3%.

Lower staff compensation is not automatically a social efficiency gain. Resources must be productively redeployed, or lost earnings and implementation burdens subtracted. The low case makes the extra implementation cost exceed savings. We do not count drug sales, participant compensation transfers or gross pharmaceutical revenue as new welfare. This channel overlaps IFP's collaborative trial work: the economic win is not separately assigned to both organizations, and gifts to 1Day Sooner are not treated as funding its separate advocacy affiliate.

Health component. The earlier review's clinical chain is retained except for the mismatched donor haircut: 100,000 potential recipients × 0.10 annual QALY gain × three months of acceleration × 25% useful-reform probability × 7.9% approval likelihood × 50% conditional incremental usefulness × organizational contribution × U.S. share, discounted for 10.5 years at 3%. The BIO historical approval benchmark informs approval and delay, not the other judgment inputs. The FDA pilot is intermediate evidence, not measured earlier treatment. The 0.1 gain is conditional on a useful product, so approval and usefulness are not already folded into it. One candidate-equivalent is a narrow health pathway, not the organization's entire portfolio. Clinical failures, participant harms, care uptake and collaboration still matter.

Combined arithmetic. The health component is 1.09 U.S. QALYs; signed income benefit is 1.62 U.S. income-equivalent healthy years. Using Coefficient Giving's comparison, income welfare is 0.5 × affected people × ln(1 + real income gain/baseline income) × the explicit causal/local/non-overlap shares, summed over individually discounted benefit years. Divide $2,424,138 by 2.71 combined years to get $900K. The report, research list and shortlist all use that same calculation.

How much confidence? Every organization-specific cohort, probability, gain and incidence assumption here is a transparent hypothesis. Primary sources identify the workstreams and economic mechanisms, not this central return. Our joint low/high cases give Conservative joint case: $11B. Not a confidence limit. Favorable joint case: $5K. Not a confidence limit. Zero implementation gives zero benefit, and net harms can eliminate a positive price. The range is not a statistical confidence interval. Inspect the exact vectors below rather than treating a precise-looking price as verified.

Costs, coverage and next evidence. Annual charity cost once. External added resource costs explicitly subtracted from native savings. Net resource saving cannot simultaneously be counted as reduced numerator AND added denominator. Need actual dossier reuse, trial-count, before/after cost and U.S. owner/payer incidence evidence. Annual-work headline removes donor funding haircut; prior factors preserved only as unknown marginal-funding sensitivity. Annual scale and causal reform probability are judgments requiring workstream evidence. Trials must change because of the reform/work package, not all trials in the industry. Include failed products that avoid resource use. Adoption and cost saving already conditional on reform; adding approvalProbability would double-discount the wrong endpoint. Existing grants and policy actors can deliver the same saving. Same CTA reform ecosystem as IFP. Attribute economic savings once across collaborators; do not present the two charities as independent wins. Exclude health benefits of reinvested R&D and drug revenue/sales from this savings channel. Five years of household gains do not automatically require five annual charity budgets, nor prove that one year's work is sufficient; the three-budget stress case tests that mismatch. Other organizational channels remain unquantified rather than assumed worthless or counted as a generic growth multiplier. Before a major funding decision, ask for current project budgets, specific counterfactual effects and recipient-level outcomes. The strongest model is the one that replaces these priors with evidence, not the one with the smallest headline price.

Model, assumptions and sensitivity

Latest original 2024 annual charitable-entity expense, charged once as an annual-work comparator, not a current marginal gift offer. Income resource savings net modeled implementation/production costs; unmeasured external health-system and public costs remain limitations.

40% of conditional patient benefit attributed to U.S. residents; not a measured geography share. Income uses only net gains during U.S. residence or U.S. consumer/owner incidence; geography adjustments in native savings and recipient cohorts are not applied twice.

patients*annualQalyGain*earlierYears*reformProbability*approvalProbability*incrementalBenefitProbability*organizationAttribution*fundingAdditionality*usShare/(1+discountRate)^delayYears; dollars per DALY = annual cost / discounted U.S. QALYs; annual-cost fundingAdditionality=1; combined price=annualCostUSD/(U.S. health QALYs + sum .5*people*ln(1+gain/baseline)*causalShare*editionShare*independentShare*sum annual discount weights).

patients
100000 people (judgment). One candidate-equivalent reaching this many recipients if useful treatment is delivered. Retained conditional scale prior, not an observed beneficiary count or a verified number of affected candidates.
annualQalyGain
0.10 QALYs/person-year (judgment). Annual incremental health gain conditional on useful treatment. This does not already average ineffective approved products; the separate incremental-benefit probability does that.
earlierYears
0.25 years (judgment). Effective-care or generation acceleration relative to the counterfactual, not time saved on an administrative step. Revised timing judgment; no measured org-specific lead.
reformProbability
0.25 fraction (judgment). Probability of an additional useful operational policy change from the modeled work. Does not credit a new gift with already enacted reforms; judgment, not measured causal probability.
approvalProbability
0.079 fraction (judgment). Historical Phase-I-to-approval likelihood of 7.9% in BIO/Informa/QLS 2011–2020. Used as an analogical prior, not an organization-specific rate; disease and modality mix can differ. [bio-2011-2020]
incrementalBenefitProbability
0.5 fraction (judgment). Probability of useful additional care conditional on approval, distinct from regulatory approval and from the conditional magnitude of benefit. Judgment, not a measured share.
organizationAttribution
0.15 fraction (judgment). Incremental organizational contribution within a collaborative policy ecosystem, conditional on useful reform. Judgment; overlapping advocates are not separate independent wins.
fundingAdditionality
1 fraction (judgment). Annual-work comparator: no extra donor haircut on full annual expense. Prior factor remains sensitivity, not a measured marginal offer.
usShare
0.4 fraction (judgment). Residence share of modeled health beneficiaries, not headquarters or spending share. Judgment; no global benefit is relabeled as U.S. benefit.
delayYears
10.5 years (judgment). Time to realization, not duration of the benefit. Clinical central uses the BIO historical 10.5-year Phase-I-to-approval average as a proxy; energy uses an explicit ten-year construction/rollout judgment. [bio-2011-2020]
discountRate
0.03 fraction (judgment). 3% annual discount convention; judgment, not an observed organizational performance parameter.
costUSD
2424138 USD/year (observed). Latest inspected original 2024 charity expense, used as an annual accounting comparator; not a current marginal funding offer. [day-990-2024]
Annual-cost versus marginal-gift boundary
1 fundingAdditionality factor (judgment). Full annual expenses estimate annual-work contribution, not return from an extra donation. Unknown marginal funding capacity remains a reservation; old haircuts retained only as sensitivities.
Income pathway central
"[{\"editionShare\":1,\"independentShare\":1,\"discountRate\":0.03,\"people\":10000,\"annualIncomeBeforeUSD\":100000,\"annualIncomeGainUSD\":950,\"years\":1,\"delayYears\":3,\"causalFactors\":{\"implementationProbability\":0.25,\"organizationAttribution\":0.15,\"fundingAdditionality\":1},\"causalShare\":0.0375}]" people, real USD, years and conditional causal factors (judgment). Central 20 trial-equivalents at illustrative $20.0M direct cost, 10% avoidable cost => $40.0M gross; subtract $2.0M extra challenge, dossier, regulator and participant-resource costs => $38.0M conditional net real-resource savings. Allocate 50% to U.S. incidence, then only 50% as net disposable income among owners/payers (other resources reinvested or offset losses): $9.5M across 10,000 people, gain $950/person, baseline $100K. Baseline reflects affluent owners/payers, not treating profit gains as $50K-average households. All counts, savings percentages, costs and incidence are judgments; $20.0M uses historical order of magnitude without pretending inflation precision. Native savings: {"trials":20,"costPerTrialUSD":20000000,"savingShare":0.1,"incrementalResourceCostUSD":2000000,"netResourceUSD":38000000,"usIncidenceShare":0.5,"netDisposableIncidenceShare":0.5,"disposableGainUSD":9500000} [income-cg] [income-evidence-1] [income-evidence-2] [income-evidence-3] [income-evidence-4]
Income pathway low
"[{\"editionShare\":1,\"independentShare\":1,\"discountRate\":0.03,\"people\":1000,\"annualIncomeBeforeUSD\":100000,\"annualIncomeGainUSD\":-5,\"years\":1,\"delayYears\":5,\"causalFactors\":{\"implementationProbability\":0.1,\"organizationAttribution\":0.05,\"fundingAdditionality\":1},\"causalShare\":0.005000000000000001}]" people, real USD, years and conditional causal factors (judgment). Central 20 trial-equivalents at illustrative $20.0M direct cost, 10% avoidable cost => $40.0M gross; subtract $2.0M extra challenge, dossier, regulator and participant-resource costs => $38.0M conditional net real-resource savings. Allocate 50% to U.S. incidence, then only 50% as net disposable income among owners/payers (other resources reinvested or offset losses): $9.5M across 10,000 people, gain $950/person, baseline $100K. Baseline reflects affluent owners/payers, not treating profit gains as $50K-average households. All counts, savings percentages, costs and incidence are judgments; $20.0M uses historical order of magnitude without pretending inflation precision. Native savings: {"trials":1,"costPerTrialUSD":20000000,"savingShare":0.02,"incrementalResourceCostUSD":500000,"netResourceUSD":-100000,"usIncidenceShare":0.2,"netDisposableIncidenceShare":0.25,"disposableGainUSD":-5000} [income-cg] [income-evidence-1] [income-evidence-2] [income-evidence-3] [income-evidence-4]
Income pathway high
"[{\"editionShare\":1,\"independentShare\":1,\"discountRate\":0.03,\"people\":100000,\"annualIncomeBeforeUSD\":75000,\"annualIncomeGainUSD\":2128,\"years\":1,\"delayYears\":1,\"causalFactors\":{\"implementationProbability\":0.5,\"organizationAttribution\":0.3,\"fundingAdditionality\":1},\"causalShare\":0.15}]" people, real USD, years and conditional causal factors (judgment). Central 20 trial-equivalents at illustrative $20.0M direct cost, 10% avoidable cost => $40.0M gross; subtract $2.0M extra challenge, dossier, regulator and participant-resource costs => $38.0M conditional net real-resource savings. Allocate 50% to U.S. incidence, then only 50% as net disposable income among owners/payers (other resources reinvested or offset losses): $9.5M across 10,000 people, gain $950/person, baseline $100K. Baseline reflects affluent owners/payers, not treating profit gains as $50K-average households. All counts, savings percentages, costs and incidence are judgments; $20.0M uses historical order of magnitude without pretending inflation precision. Native savings: {"trials":100,"costPerTrialUSD":20000000,"savingShare":0.2,"incrementalResourceCostUSD":20000000,"netResourceUSD":380000000,"usIncidenceShare":0.7,"netDisposableIncidenceShare":0.8,"disposableGainUSD":212800000} [income-cg] [income-evidence-1] [income-evidence-2] [income-evidence-3] [income-evidence-4]

Initial estimate — diagnostic comparison, superseded: Cost: $2.4M; USA health QALYs: 7.50; all-population health QALYs: 12.50. 100000*.1*.5*.25*.1*.2*.5*.6 = 7.50 U.S. QALYs.

No added patient benefit: Cost: $2.4M; USA health QALYs: 0.00; all-population health QALYs: 0.00. No attributable change in effective treatment access or existing funders replace the gift.

Participant or evidence harm: Cost: $2.4M; USA health QALYs: -6.00; all-population health QALYs: -10.00. Illustrative stress case; not an observed harm amount.

Previous health-only review, superseded diagnostic: Cost: $2.4M; USA health QALYs: 0.38; all-population health QALYs: 0.95. {"patients":100000,"annualQalyGain":0.1,"earlierYears":0.25,"reformProbability":0.25,"approvalProbability":0.079,"incrementalBenefitProbability":0.5,"organizationAttribution":0.15,"fundingAdditionality":0.35,"usShare":0.4,"delayYears":10.5,"discountRate":0.03,"costUSD":2424138}

Combined health and income central hypothesis: Cost: $2.4M; USA health QALYs: 1.09; all-population health QALYs: 2.72. Income-equivalent healthy years: 1.62. Annual-cost comparison; fundingAdditionality=1. Health vector: {"patients":100000,"annualQalyGain":0.1,"earlierYears":0.25,"reformProbability":0.25,"approvalProbability":0.079,"incrementalBenefitProbability":0.5,"organizationAttribution":0.15,"fundingAdditionality":1,"usShare":0.4,"delayYears":10.5,"discountRate":0.03,"costUSD":2424138}. Income paths are explicit hypotheses, discounted separately; not confidence limits. Low stress case has implementation cost exceeding saved research resources. Staff/CRO wages lost are not automatically social savings; require labor reassigned productively or subtract lost income. Avoid lower compensation framed as efficiency. Quality losses, privacy and participant harm belong in signed health/economic harm scenarios.

Conservative joint hypothesis: Cost: $2.4M; USA health QALYs: 0.00; all-population health QALYs: 0.00. Income-equivalent healthy years: 0.00. Annual-cost comparison; fundingAdditionality=1. Health vector: {"patients":10000,"annualQalyGain":0.05,"earlierYears":0.08333333333333333,"reformProbability":0.1,"approvalProbability":0.05,"incrementalBenefitProbability":0.25,"organizationAttribution":0.05,"fundingAdditionality":1,"usShare":0.2,"delayYears":15,"discountRate":0.03,"costUSD":2424138}. Income paths are explicit hypotheses, discounted separately; not confidence limits. Low stress case has implementation cost exceeding saved research resources. Staff/CRO wages lost are not automatically social savings; require labor reassigned productively or subtract lost income. Avoid lower compensation framed as efficiency. Quality losses, privacy and participant harm belong in signed health/economic harm scenarios.

Favorable joint hypothesis: Cost: $2.4M; USA health QALYs: 254.74; all-population health QALYs: 363.91. Income-equivalent healthy years: 203.73. Annual-cost comparison; fundingAdditionality=1. Health vector: {"patients":500000,"annualQalyGain":0.1,"earlierYears":0.5,"reformProbability":0.5,"approvalProbability":0.15,"incrementalBenefitProbability":0.75,"organizationAttribution":0.3,"fundingAdditionality":1,"usShare":0.7,"delayYears":5,"discountRate":0.03,"costUSD":2424138}. Income paths are explicit hypotheses, discounted separately; not confidence limits. Low stress case has implementation cost exceeding saved research resources. Staff/CRO wages lost are not automatically social savings; require labor reassigned productively or subtract lost income. Avoid lower compensation framed as efficiency. Quality losses, privacy and participant harm belong in signed health/economic harm scenarios.

Three annual budgets for the same effects: Cost: $7.3M; USA health QALYs: 1.09; all-population health QALYs: 2.72. Income-equivalent healthy years: 1.62. Same health and income denominator but three years of charity expense, not three repeated copies of the benefits.

No independent economic benefit: Cost: $2.4M; USA health QALYs: 1.09; all-population health QALYs: 2.72. Income-equivalent healthy years: 0.00. Same health model with zero independent economic effect; tests failure, not a claim that omitted evidence proves zero value.

Prior marginal-funding haircut applied as sensitivity: Cost: $2.4M; USA health QALYs: 0.38; all-population health QALYs: 0.95. Income-equivalent healthy years: 0.57. Legacy funding factor 0.35 on both components; not the annual-cost central estimate or verified marginal gift return.

Counterfactual: Other advocates and regulators may enact the same reform; existing funders may support the same work and many affected drug candidates fail.

Attribution: Annual-work causal contribution and implementation probability apply once to each pathway. FundingAdditionality=1 for the annual-cost central comparison; old marginal-funding factors remain sensitivities only. Do not credit future gifts with past achievements or count collaborative wins twice.

Central/low/high are transparent joint hypotheses, not posterior estimates or confidence intervals. Distinct conditionals are logically meaningful but no source identifies their product. Show undiscounted conditional benefits and total causal share so compounded skepticism is visible. Do not multiply portfolio scale by an invented count. No universal GDP-to-income conversion. Low stress case has implementation cost exceeding saved research resources. Staff/CRO wages lost are not automatically social savings; require labor reassigned productively or subtract lost income. Avoid lower compensation framed as efficiency. Quality losses, privacy and participant harm belong in signed health/economic harm scenarios.

Sensitivity

  • Conservative joint case: $11B. Not a confidence limit.
  • Favorable joint case: $5K. Not a confidence limit.
  • No income: $2.2M.
  • Three annual budgets: $2.7M.
  • Legacy donor haircut: $2.6M. Not a measured marginal gift offer.

Unresolved inputs

  • U.S. versus international budget and beneficiary mix
  • Attributable policy change and clinical-development time saved
  • Net participant harms and clinical-success rate
  • Current unrestricted runway and external research costs
  • Reconciled legal recipient and payment dates for Coefficient's $1.9M listing
  • 2025/2026 program accounts and CPO collaborator-grant income
  • CTD archive acquisitions, reuse and counterfactual development timing
  • Measured net disposable-income gains, incidence, causal scale and public-resource costs to replace income hypotheses

Health and income breakdown

For the modeled $2.4M: 1.09 health QALYs + 1.62 income-equivalent healthy years in USA: $895K per DALY. Income equivalents are welfare comparisons, not observed QALYs or DALYs.

Method and caveats.

5. Funding and previous grants

We inspected original IRS-derived rendered Form 990s for 2022, 2023 and 2024. Total expenses were $1,554,943; $2,832,663; and $2,424,138, a three-year mean of $2,270,581. The 2023 total includes a separately disclosed $394,096 settlement expense; removing only that one-off gives a descriptive mean of $2,139,216. We retain gross totals and do not call this adjusted figure an audited recurring budget.

2024 spending. Part IX assigns $2,262,397 (93.3%) to programs, $150,212 (6.2%) to management/general and $11,529 (0.5%) to fundraising. Staff compensation, benefits and payroll taxes total $1,153,259 (47.6%). Nonemployee services total $819,238 (33.8%); Schedule O itemizes $455,638 contractors, $344,784 payroll fees, $10,965 honoraria and $7,851 payroll-management fees. Payroll fees are the filing's category, not proof of an additional equivalent salary amount or external research expenditure. Travel is $176,298, conferences $77,131 and grants $86,450. These are organizational classifications; no public allocation ties them to U.S. CTA, CPO, vaccine work or the modeled reform.

2024 revenue was $1,417,665 and net assets without donor restrictions ended at $2,015,836. Cash and savings totaled $2,048,188; liabilities were $51,644. Net assets equal roughly ten months of 2024 expenses, a historical ratio rather than current runway. The filing reports no independent financial audit/review and no written conflict, whistleblower or retention policies in that year. Ask for updated governance and accounting documents before treating these historical disclosures as current practices.

The July 2026 financial disclosure reports $12.8M cumulative charity funding, including $4.6M from Coefficient Giving in its embedded chart. It separately reports $2.9M for the affiliated 501(c)(4) 1Day Action. Action's own disclosure itemizes $1.0M received in November 2023 and $1.9M in April 2026. Coefficient's fund listing instead labels a $1.9M clinical-policy grant “1Day Sooner,” May 2026. The matching amount suggests an affiliate/date-label difference, but recipient metadata is unresolved; we do not add this grant to charity cash or count it twice. The charity also discloses a distinct $650,000 individual donation in April 2026. Cumulative receipts are not unrestricted money available today.

Room for more funding remains unverified. Historical deficits, a live donation page and worthwhile proposals do not establish a current marginal gap after later grants. Request the current charity cash forecast, restrictions and grant-payment schedule, CPO collaborator income, program/country budget, and the next work that would be delayed without an additional gift. Donor additionality is stronger if a defined participant-support or archive milestone is currently unfunded and not replaceable by partner grants. It is weaker if ordinary gifts release an existing funder's money or finance work already committed. The model's 50% factor remains an explicit assumption until such evidence is supplied.

Annual expenses

Organization-level spending, including programs, administration and fundraising. The research list averages three comparable, consecutive full fiscal years when available.

  • FY 2022: $1.6M; 1Day Sooner Inc, 12-month period, Original IRS-derived rendered Form 990 total expenses. Source
  • FY 2023: $2.8M; 1Day Sooner Inc, 12-month period, Original IRS-derived rendered Form 990 total expenses. Source
  • FY 2024: $2.4M; 1Day Sooner Inc, 12-month period, Original IRS-derived rendered Form 990 total expenses. Source

6. Sources

  1. Clinical Trial Abundance. 1Day Sooner. Published: not stated; retrieved: 2026-09-30.
  2. Clinical Trial Abundance Symposium 2026. 1Day Sooner. Published: not stated; retrieved: 2026-09-30.
  3. CTD Commons launch. 1Day Sooner. Published: 2026-01-26; retrieved: 2026-09-30.
  4. Finances and Transparency. 1Day Sooner. Published: not stated; retrieved: 2026-09-30.
  5. IRS-derived filing index. IRS via ProPublica. Published: not stated; retrieved: 2026-09-30.
  6. Abundance and Growth fund grants. Coefficient Giving. Published: not stated; retrieved: 2026-09-30.
  7. Donate. 1Day Sooner. Published: not stated; retrieved: 2026-09-30.
  8. 2022 original Form 990. IRS via ProPublica. Published: not stated; retrieved: 2026-09-30.
  9. 2023 original Form 990. IRS via ProPublica. Published: not stated; retrieved: 2026-09-30.
  10. 2024 original Form 990. IRS via ProPublica. Published: not stated; retrieved: 2026-09-30.
  11. 2024 Schedule O. IRS via ProPublica. Published: not stated; retrieved: 2026-09-30.
  12. Affiliate funding disclosure. 1Day Action. Published: not stated; retrieved: 2026-09-30.
  13. Cooperative Participant Organization. 1Day Sooner. Published: not stated; retrieved: 2026-09-30.
  14. CPO Frequently Asked Questions. 1Day Sooner. Published: not stated; retrieved: 2026-09-30.
  15. Participant Council. 1Day Sooner. Published: not stated; retrieved: 2026-09-30.
  16. Challenge Model Development. 1Day Sooner. Published: not stated; retrieved: 2026-09-30.
  17. Briefs & Reports. 1Day Sooner. Published: not stated; retrieved: 2026-09-30.
  18. CTD Commons. CTD Commons. Published: not stated; retrieved: 2026-09-30.
  19. Recruitment under way in hepatitis C study. NIHR Oxford BRC. Published: not stated; retrieved: 2026-09-30.
  20. Systematic review of human challenge trials, designs and safety. Clinical Infectious Diseases. Published: not stated; retrieved: 2026-09-30.
  21. Expedited IND pilot launch, September 15 2026. FDA. Published: not stated; retrieved: 2026-09-30.
  22. BIO/Informa/QLS Clinical Development Success Rates and Contributing Factors 2011–2020. BIO / Informa / QLS. Published: not stated; retrieved: 2026-09-30.
  23. Expedited IND pilot launch and initial 8–10 sponsor/QRI pairs. FDA. Published: 2026-09-15; retrieved: 2026-09-30.
  24. Cost-effectiveness: health and log-income comparison. Coefficient Giving. Published: not stated; retrieved: 2026-09-30.
  25. CTA expressly seeks cheaper evidence generation and greater reuse, through incremental policy and movement building.. www.1daysooner.org. Published: not stated; retrieved: 2026-09-30.
  26. 1Day authors Fraser-Urquhart/Morrison describe cheaper challenge-agent manufacturing/testing and earlier rejection of ineffective products. ifp.org. Published: not stated; retrieved: 2026-09-30.
  27. Primary analysis of 59 FDA-approved novel agents in 2015–16 estimated median pivotal efficacy-trial cost $19.0M; historical modeled sponsor cost, not observed 1Day saving or 2026 price.. pmc.ncbi.nlm.nih.gov. Published: not stated; retrieved: 2026-09-30.
  28. 2014 HHS-sponsored operational cost model estimated selected cheaper-facility/in-home strategies could save up to $800K/I, $4.3M/II and $9.1M/III. aspe.hhs.gov. Published: not stated; retrieved: 2026-09-30.